{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=oral+dexamethasone&page=9", "query": { "intervention": "oral dexamethasone", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 744, "total_pages": 75, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=oral+dexamethasone&page=10&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=oral+dexamethasone&page=8&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T09:16:52.156Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05070247", "title": "A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer", "Hepatocellular Cancer", "Mesothelioma", "Breast Cancer", "Gastric Cancer", "Esophageal Cancer", "Nasopharyngeal Cancer", "Kidney Cancer", "Squamous Cell Cancer of Head and Neck (SCCHN)", "Non-small Cell Lung Cancer (NSCLC), Non-squamous" ], "interventions": [ { "name": "TAK-500", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2022-04-14", "completion_date": "2025-01-06", "has_results": true, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-10-22T09:16:52.156Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Duarte, California • La Jolla, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05070247" }, { "nct_id": "NCT01670097", "title": "Dexamethasone Dyspnea Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Cancers", "Hematologic Disorder", "Solid Tumors" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Questionnaires", "type": "BEHAVIORAL" }, { "name": "Spirometer", "type": "DEVICE" }, { "name": "Phone Calls", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BEHAVIORAL", "DEVICE", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2013-01", "completion_date": "2021-01-26", "has_results": true, "last_update_posted_date": "2021-02-17", "last_synced_at": "2026-10-22T09:16:52.156Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01670097" }, { "nct_id": "NCT00404066", "title": "Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Lapatinib", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "George Albert Fisher", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "18 Years to 70 Years · Female only" }, "enrollment_count": 21, "start_date": "2006-10", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2017-12-22", "last_synced_at": "2026-10-22T09:16:52.156Z", "location_count": 2, "location_summary": "San Jose, California • Stanford, California", "locations": [ { "city": "San Jose", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00404066" }, { "nct_id": "NCT01159574", "title": "Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "dexamethasone", "type": "DRUG" }, { "name": "clarithromycin", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 121, "start_date": "2010-08", "completion_date": "2015-05-05", "has_results": true, "last_update_posted_date": "2019-06-11", "last_synced_at": "2026-10-22T09:16:52.156Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01159574" }, { "nct_id": "NCT00573391", "title": "Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Velcade, Thalidomide, and Dexamethasone", "type": "DRUG" }, { "name": "Velcade, Melphalan, and Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arkansas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2006-08", "completion_date": "2008-07", "has_results": true, "last_update_posted_date": "2011-08-12", "last_synced_at": "2026-10-22T09:16:52.156Z", "location_count": 1, "location_summary": "Little Rock, Arkansas", "locations": [ { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00573391" }, { "nct_id": "NCT01329289", "title": "SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma in Relapse", "Multiple Myeloma" ], "interventions": [ { "name": "SOM230", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2011-12", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2016-02-12", "last_synced_at": "2026-10-22T09:16:52.156Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01329289" }, { "nct_id": "NCT04923893", "title": "A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Cilta-cel", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 743, "start_date": "2021-08-19", "completion_date": "2036-09-22", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-22T09:16:52.156Z", "location_count": 19, "location_summary": "San Francisco, California • New Haven, Connecticut • Miami, Florida + 13 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04923893" }, { "nct_id": "NCT03334487", "title": "Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Rovalpituzumab tesirine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-03-15", "completion_date": "2018-12-20", "has_results": false, "last_update_posted_date": "2018-12-26", "last_synced_at": "2026-10-22T09:16:52.156Z", "location_count": 27, "location_summary": "Chandler, Arizona • Scottsdale, Arizona • Fresno, California + 23 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03334487" }, { "nct_id": "NCT01946477", "title": "Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 186, "start_date": "2014-05-29", "completion_date": "2025-05-26", "has_results": true, "last_update_posted_date": "2026-06-15", "last_synced_at": "2026-10-22T09:16:52.156Z", "location_count": 33, "location_summary": "Tucson, Arizona • Greenbrae, California • Los Angeles, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pleasant Hill", "state": "California" }, { "city": "Whittier", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01946477" }, { "nct_id": "NCT00097981", "title": "A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Thalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "DOXIL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 225, "start_date": "2005-01", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2017-04-07", "last_synced_at": "2026-10-22T09:16:52.156Z", "location_count": 58, "location_summary": "Fountain Valley, California • Greenbrae, California • La Verne, California + 55 more", "locations": [ { "city": "Fountain Valley", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "La Verne", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00097981" } ] }